238 related articles for article (PubMed ID: 36460861)
1. Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X.
Hao Y; Xu M; Zhou H; Si J; Fang Y; Xu C; Song Z
Med Oncol; 2022 Dec; 40(1):34. PubMed ID: 36460861
[TBL] [Abstract][Full Text] [Related]
2. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
Pang L; Huang Y; Zhuang W; Zhang Y; Liao J; Hao Y; Hao F; Wang G; Chen ZC; Zhu Y; Li M; Song Z; Deng BP; Li J; Zhang L; Fang W
Clin Cancer Res; 2024 Jun; 30(12):2636-2646. PubMed ID: 38578683
[TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.
Hao Y; Xu M; Jin J; Si J; Xu C; Song Z
Cancer Med; 2023 Aug; 12(15):15903-15911. PubMed ID: 37306192
[TBL] [Abstract][Full Text] [Related]
4. Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.
Huang Y; Xu C; Sun Y; Wang W; Li X; Liao J; Pang L; Zeng L; Li J; Wang X; Zhang Q; Xie Z; Xiao L; Gan J; Fang W
Lung Cancer; 2022 Oct; 172():117-123. PubMed ID: 36063602
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
6. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.
Kim TH; Choi JH; Ahn MS; Lee HW; Kang SY; Choi YW; Koh YW; Sheen SS
BMC Cancer; 2024 Jan; 24(1):70. PubMed ID: 38216948
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in
Zhang Y; Zeng H; Qi C; Tan S; Huang Q; Pu X; Suda K; Santarpia M; Tian P; Li Y
Transl Lung Cancer Res; 2024 Apr; 13(4):875-884. PubMed ID: 38736500
[TBL] [Abstract][Full Text] [Related]
8. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them].
Shi Y; Li P; Li B; Zhang F; Huang S; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):299-305. PubMed ID: 31109439
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
[TBL] [Abstract][Full Text] [Related]
10. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
Borgeaud M; Parikh K; Banna GL; Kim F; Olivier T; Le X; Addeo A
J Thorac Oncol; 2024 Mar; ():. PubMed ID: 38499147
[TBL] [Abstract][Full Text] [Related]
13. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Gursoy P; Tatli AM; Erdem D; Goker E; Celik E; Demirci NS; Sakin A; Atci MM; Bayram E; Telli TA; Bilgin B; Bilici A; Akangunduz B; Balli S; Demirkazik A; Selçukbiricik F; Menekse S; Cavdar E; Ozturk A; Bekmez ET; Turhal S; Kilickap S; Yildirim HÇ; Oyan B; Aksoy A; Turkoz FP; Kut E; Katgi N; Sakalar T; Akyol M; Ellez Hİ; Topcu A; Erdoğan AP; Pilanci KN; Hedem E; Arak H; Akdeniz N; Alan Ö; Yapar B; Nart D; Yumuk PF
J Cancer Res Clin Oncol; 2023 Feb; 149(2):865-875. PubMed ID: 35381885
[TBL] [Abstract][Full Text] [Related]
14. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
15. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
Yu X; Si J; Wei J; Wang Y; Sun Y; Jin J; Zhang X; Ma T; Song Z
Cancer Med; 2023 Mar; 12(5):5630-5638. PubMed ID: 36380563
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
19. Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.
Wang Y; Wu G; Li R; Luo Y; Huang X; He L; Zhong H; Xiong S
Front Public Health; 2021; 9():677862. PubMed ID: 34222178
[No Abstract] [Full Text] [Related]
20. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]